Table 2.
Method of anticoagulation | Number of patients (n=217) |
---|---|
Warfarin | 78 (35.9%) |
NOAC | 116 (53.5%) |
Dabigatran | 10 (4.6%) |
Rivoraxaban | 45 (20.7%) |
Apixaban | 60 (27.6%) |
Warfarin switched to NOAC | 4 (1.8%) |
No anticoagulation | 21 (9.7%) |
Patient declined | 3 (1.4%) |
Adverse event with anticoagulation | 3 (1.4%) |
End of life / hospice | 2 (0.9%) |
Peri transplant | 3 (1.4%) |
Unknown | 10 (4.6%) |